Clinical Trial Update: Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update indicates pembrolizumab is being studied for locally advanced and/or recurrent orbital or periocular cutaneous squamous cell car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: RECRUITING